Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

Transcription profiling of human prostate cancer cells over-expressing androgen receptor following dihydrotestosterone treament

ABSTRACT: dose and time dependent responses of dihydrotestosterone in androgen receptor over-expressing prostate cancer cells.

ORGANISM(S): Homo sapiens

SUBMITTER: Kati Waltering

PROVIDER: E-MEXP-2286 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Publications

Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.

Waltering Kati K KK Helenius Merja A MA Sahu Biswajyoti B Manni Visa V Linja Marika J MJ Jänne Olli A OA Visakorpi Tapio T

Cancer research 20091006 20

Androgen receptor (AR) is known to be overexpressed in castration-resistant prostate cancer. To interrogate the functional significance of the AR level, we established two LNCaP cell sublines expressing in a stable fashion two to four times (LNCaP-ARmo) and four to six times (LNCaP-ARhi) higher level of AR than the parental cell line expressing the empty vector (LNCaP-pcDNA3.1). LNCaP-ARhi cell line grew faster than the control line in low concentrations, especially in 1 nmol/L 5alpha-dihydrotes ...[more]

PMID: 19808968

Similar Datasets

Project description:LSD1 (also known as KDM1A) is a histone demethylase and a key regulator of gene expression in embryonic stem cells and cancer. LSD1 was initially identified as a transcriptional repressor via its demethylation of active histone H3 marks (di-methyl lysine 4 [2MK4]). In prostate cancer, specifically, LSD1 also co-localizes with the AR and demethylates repressive 2MK9 histone marks from androgen-responsive AR target genes, facilitating androgen-mediated induction of AR-regulated gene expression and androgen-induced proliferation in androgen-dependent cancers. Recently, it was shown that treatment with high doses of androgens (e.g.10-fold higher doses than those required for induction of expression of androgen-activated genes such as PSA) recruits LSD1 and AR to an enhancer within the AR; this AR and LSD1 recruitment represses AR transcription. Thus, LSD1 appears to play a role in mediating both the proliferative and repressive phases of the biphasic androgen dose-response curve. For these reasons, we hypothesized that LSD1 might be important for maintenance of AR signalling in castration-resistant prostate cancer (CRPC) tumors. However, in this report, we describe a distinct role of LSD1 as a driver of proliferation and survival of prostate cancer cells, including CRPC cells, irrespective of androgens or even AR expression. Specifically, LSD1 activates expression of cell cycle, mitosis, and embryonic stem cell maintenance pathways that are enriched in lethal prostate cancers - pathways not activated by androgens. Finally, we observe that treatment with a new LSD1 inhibitor potently and specifically suppresses LSD1 function and suppresses CRPC growth and survival in vitro and in vivo. Our data place LSD1 as a key driver of androgen-independent survival in lethal prostate cancers and demonstrate the potential of LSD1-directed therapies in the near-term. The enclosed files are from microarrays experiments after suppressing LSD1 with RNAi or stimulating cells with the androgen agonist dihydrotestosterone (DHT).

Dataset Information

Transcription profiling of human prostate cancer cells over-expressing androgen receptor following dihydrotestosterone treament

Publications

Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure